Screener
Adaptive Biotechnologies ADPT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating lease right-of-use assets and liabilities | (2,600) | (2,035) |
| Deferred revenue | 4,004 | (3,326) |
| Other | (98) | (6) |
| Net cash used in operating activities | (9,537) | (28,484) |
| Investing activities | ||
| Purchases of property and equipment | (796) | (1,259) |
| Purchases of marketable securities | (38,863) | (50,654) |
| Proceeds from maturities of marketable securities | 48,802 | 77,486 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's operating cash flow?
- Adaptive Biotechnologies (ADPT) reported operating cash flow of -$9.54M in Q1 2026.
- How has Adaptive Biotechnologies's operating cash flow changed year-over-year?
- Adaptive Biotechnologies's operating cash flow increased by 66.5% year-over-year, from -$28.48M to -$9.54M.
- What is the long-term trend for Adaptive Biotechnologies's operating cash flow?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's operating cash flow has grown at a -29.3% compound annual growth rate (CAGR), from -$192.73M to -$48.04M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Adaptive Biotechnologies's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude